Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Spectral Medical Inc T.EDT

Alternate Symbol(s):  EDTXF

Spectral Medical Inc. is a Canada-based late-stage theragnostic company advancing therapeutic options for sepsis and septic shock. The Company develops and commercializes a treatment for septic shock utilizing its Endotoxin Activity Assay (EAA) diagnostic and the Toraymyxin therapeutic (PMX). PMX is a therapeutic hemoperfusion device that removes endotoxin, which can cause sepsis, from the bloodstream and is guided by the Company’s EAA. PMX is approved for therapeutic use in Japan and Europe and has been used safely and effectively on more than 340,000 patients to date. It has pioneered the development of biochemical markers for the clinical syndrome known as septic shock. It is continuing its legacy business of manufacturing and selling certain proprietary reagents. It develops, produces and markets recombinant proteins, antibodies and calibrators. These materials are sold for use in research and development, as well as in products manufactured by other diagnostic companies.


TSX:EDT - Post by User

Post by palinc2000on Feb 26, 2024 12:36pm
148 Views
Post# 35899380

Unexplained

Unexplained Assuming Spectral mgmt take their  fiduciary responsibility seriously it is inconceivable that they accepted a minucule milestone payment of only 2 million dollrs cad from Baxter who has a market Cap of over 21 Billion US Dollrs ...if in fact the odds of successful results  after the 90 patient milestone is reported by some to be over 95 %,,,,,Especially in light of apparently over 30% dilution will be needed to get us to FDA approval......SOMETHING DOES NOT ADD UP

Why was the 2 million milestone payment not mentioned in the PR and not mentioned in the CC until asked at the end of the CC

Why have they not disclosed the milestone payment upon FDA approval?
There are no competitive downfall in revealing this amount .....

Some say that Baxter is calling the shot  ....that makes no sense

I have not encounterd bashers in this MB as questioning mgmts actions in search of the truth is what is needed,,,The endless pumping  by some contributes NOTHING....
<< Previous
Bullboard Posts
Next >>